Clinical trial
A Phase Ⅱ, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus Nephritis
NCT05680480 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅱ, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Telitacicept in Lupus Nephritis
- Lead sponsor
- RemeGen Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 17, 2023
- Completion date
- January 31, 2026
- Enrollment
- 120 (estimated)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.